<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hereditary spastic paraplegia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hereditary spastic paraplegia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hereditary spastic paraplegia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Puneet Opal, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Senda Ajroud-Driss, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H12449526">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary spastic paraplegia (HSP) refers to a group of familial diseases that are characterized by progressive degeneration of the corticospinal tracts. Clinically, they present with lower limb spasticity and weakness.
        </p>
        <p class="headingAnchor" id="H2276859">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         HSP, also called familial spastic paraplegia, was initially referred to as Strumpell-Lorrain disease, a name given for the two physicians who in the late 19th century independently described key features of spastic paraplegia. It has become evident that HSP is not one disease but a mixed group of genetically heterogeneous conditions that result in broadly overlapping clinical features.
        </p>
        <p>
         HSPs are clinically differentiated into "pure" forms if spastic paraplegia with bladder involvement is the only clinical finding, and "complicated" (or complex) forms if there are additional neurologic or systemic abnormalities. In the pre-genetic era, attempts were made to further classify HSP based upon age of onset, degree of spasticity, and rate of progression [
         <a href="#rid1">
          1
         </a>
         ]. Today, however, the classification of HSP is increasingly based upon genetics, especially given the phenotypic heterogeneity of HSP within the same family harboring the same genetic defect.
        </p>
        <p>
         The genetic classification of HSP is based upon mode of inheritance, chromosomal locus, and causative mutation (if known). Hereditary spastic paraplegias include autosomal dominant, autosomal recessive, and X-linked forms. The genetic loci are designated as SPG (for SPastic parapleGia) and are numbered sequentially as SPG1, SPG2, SPG3, and so on  (
         <a class="graphic graphic_table graphicRef95449" href="/z/d/graphic/95449.html" rel="external">
          table 1
         </a>
         ). The numbering of the SPGs is based upon the order of locus discovery and not on the mechanism of genetic transmission. The number of loci continues to expand and is available from the Online Mendelian Inheritance in Man at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2FphenotypicSeries%2FPS303350&amp;token=87jLzclRwWxNoI%2BQq5Gg77Noi02PV7mp%2FAKVy6h%2BWKhVJ2GuQIdOY67gfjcbGv3aAB%2BTXptn4LavUG7wz%2FQ8OA%3D%3D&amp;TOPIC_ID=14152" target="_blank">
          Phenotypic Series - PS303350
         </a>
         .
        </p>
        <p>
         The correlation of clinical classification (pure or complicated) with genetic classification (SPG type) is imperfect, and some genetic types of HSP are associated with both pure and complicated phenotypes [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26506305">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the HSPs are genetically diverse, a shared pathway for these disorders is length-dependent degeneration of the corticospinal tract axons, which is maximal in the thoracic spinal cord, and dorsal column axons in the fasciculus gracilis, which is maximal in the cervical cord [
         <a href="#rid2">
          2,3
         </a>
         ]. Thus, the longest motor and sensory axons in the central nervous system appear to be particularly vulnerable to the degenerative process. Although primarily considered as a disorder of long-tract spinal cord axons, the neuropathology of many types of HSP involves additional components of the central and peripheral nervous system, including abnormalities of shorter axons in the cerebellum and corpus callosum, lower motor neurons, peripheral nerves, and myelin. Laboratory and genetic studies suggest a variety of molecular causes for HSP, including disruption in intracellular trafficking, nucleotide metabolism, synapse formation and axon development, axonal transport, mitochondrial function, and myelin maintenance and assembly [
         <a href="#rid2">
          2-5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26506245">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         HSP is rare, with an overall prevalence of approximately 1 to 10 per 100,000 [
         <a href="#rid2">
          2,3,6
         </a>
         ]. The disorder affects diverse ethnic groups. The age of onset is variable and ranges from neonates to older adults.
        </p>
        <p class="headingAnchor" id="H2276984">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases, HSP presents with gait impairment caused by leg weakness and spasticity along with other corticospinal signs, such as brisk tendon reflexes and extensor plantar (ie, Babinski) responses. The spasticity is more or less symmetric. Based upon the severity and progression, gait disability may range from mild to severe. In addition, there can be subtle dorsal column impairment in the legs with diminished vibratory sensation distally, though sensory complaints are usually minimal [
         <a href="#rid7">
          7
         </a>
         ]. Bladder dysfunction is relatively common in HSP, and urinary urgency may be an early or presenting sign. Pes cavus and hammer toes may be seen in HSP.
        </p>
        <p>
         With the pure types of HSP, the symptoms are restricted to involvement of the longest tracts of the spinal cord. Speech is not affected, nor is there weakness in the bulbar muscles or arms.
        </p>
        <p>
         With the complicated types of HSP, paraplegia coexists with additional neurologic or systemic derangements. Examples of complicated HSP types include spastic paraplegia in combination with the following manifestations [
         <a href="#rid2">
          2,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral neuropathy in SPG2, 3A, 5, 6, 7, 10, 25, 27, 30, 31, 55, 56, 74, 75, 76, and 79
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distal amyotrophy in SPG3A (rarely), 4 (rarely), 5, 10 11, 14, 15, 17, 20, 26, 30, 38, 39, 41, 43, and 55
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intellectual disability in SPG1, 11, 14, 16,18, 20, 22, 26, 27, 32, 44, 45, 47, 49, 50, 51, 52, 53, 54, 56, 75, 78, 81, and 82
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dementia in SPG4, 15, 21, 35, 46, and 78
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MRI brain abnormalities in SPG1, 2, 5, 7 (variably), 11, 15, 18, 21, 32, 35, 44, 46, 47, 49, 50, 54, 56, 75, 78, 81, and 82
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ataxia in SPG7, 21, 22, 27, 30, 32, 46, 49, 62, 76, and 78
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extrapyramidal symptoms in SPG21, 35, and 56
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visual loss in SPG15, 16, 45, 46, 54, 55, 74, 75, 79, and 81
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hearing loss in SPG29
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skeletal abnormalities or dysmorphic features in SPG25, 49, 50, 51, 52, and 53
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epilepsy in SPG6, 35, 47, 51, and 81
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysarthria in SPG7, 15, 22, 24, 27, 35, 43, 44, and 54
        </p>
        <p>
        </p>
        <p>
         In addition to age of onset, the rate of progression and severity of different types of HSP are highly variable among and even within specific genetic types. Several patterns of progression have been described, including a relatively nonprogressive course, inexorable decline, and progressive worsening that stabilizes over time, reaching a functional plateau with little further increase in disability. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H18459493">
         <span class="h2">
          Autosomal dominant HSP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common autosomal dominant HSPs  (
         <a class="graphic graphic_table graphicRef95449" href="/z/d/graphic/95449.html" rel="external">
          table 1
         </a>
         ) are SPG4 and SPG3A [
         <a href="#rid9">
          9
         </a>
         ]. SPG4 accounts for 33 to 40 percent of autosomal dominant HSPs [
         <a href="#rid9">
          9,10
         </a>
         ], while SPG3 accounts for 6 to 10 percent of cases [
         <a href="#rid7">
          7,9
         </a>
         ]. SPG31 accounts for 4 to 6 percent of autosomal dominant HSPs [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Autosomal dominant HSPs usually cause a pure HSP phenotype, with the exceptions of SPG9, 17, 29, 36, and 38.
        </p>
        <p>
         Below we describe the features of some of the more common autosomal dominant HSPs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG3A
         </strong>
         is characterized in most cases by a pure spastic paraplegia with onset in childhood [
         <a href="#rid2">
          2
         </a>
         ]. Symptoms usually start before the age of 10 years and the course may be nonprogressive. Because of this early onset, sporadic cases have been misdiagnosed as cerebral palsy. Less often, SPG3A is associated with complicated HSP features, including motor-sensory axonal neuropathy, distal muscle wasting, a thin corpus callosum, and cognitive impairment [
         <a href="#rid12">
          12-15
         </a>
         ]. SPG3A is caused by mutations in the ATL1 gene [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG4
         </strong>
         is the most common form of autosomal dominant HSP [
         <a href="#rid2">
          2,3
         </a>
         ]. It is typically characterized by a pure HSP phenotype. The mean age of onset is 34 years [
         <a href="#rid10">
          10
         </a>
         ], but varies considerably with a range that extends from birth to the eighth decade due to incomplete penetrance [
         <a href="#rid7">
          7
         </a>
         ]. As with many other pure forms of HSP, a minority of SPG4 cases are associated with complicated features, such as cognitive impairment, psychiatric disorders, ataxia, thin corpus callosum, or muscle wasting [
         <a href="#rid17">
          17-22
         </a>
         ]. There can be significant variability even in the same family, suggesting a role for modifiers [
         <a href="#rid23">
          23
         </a>
         ]. SPG4 is caused by mutations in the SPAST gene [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG6
         </strong>
         typically exhibits a pure HSP phenotype. It caused by mutations in the NIPA1 gene [
         <a href="#rid3">
          3,26
         </a>
         ]. Onset is usually in late adolescence or early adulthood, but ranges from 8 to 40 years [
         <a href="#rid3">
          3
         </a>
         ]. Rare cases are "complicated" with variable peripheral neuropathy or epilepsy [
         <a href="#rid2">
          2,27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG8
         </strong>
         is a relatively frequent autosomal dominant, pure form of HSP caused by mutations in the KIAA1096 gene [
         <a href="#rid29">
          29
         </a>
         ]; onset ranges from 18 to 60 years [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG10
         </strong>
         is characterized by a pure, early-onset spastic paraplegia caused by mutations in the KIF5A gene [
         <a href="#rid30">
          30
         </a>
         ]. The age of onset ranges from 2 to 51 years [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG17
         </strong>
         is characterized by a complicated HSP phenotype with spastic paraparesis in the legs and marked weakness and atrophy of hand muscles (a pattern also known as Silver syndrome) [
         <a href="#rid2">
          2
         </a>
         ]. The age of onset is variable [
         <a href="#rid3">
          3
         </a>
         ]. The cause is mutations in the BSCL2 gene that encodes seipin, a protein that is mainly localized to the endoplasmic reticulum membrane [
         <a href="#rid31">
          31
         </a>
         ]. Mutations in this gene cause two other allelic disorders, which are congenital lipodystrophy type 2 and autosomal dominant distal hereditary motor neuropathy type VA [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG31
         </strong>
         is a relatively frequent autosomal dominant HSP that typically exhibits a pure HSP phenotype, although occasionally complicated by peripheral neuropathy [
         <a href="#rid2">
          2,33
         </a>
         ]. Limited data suggest a bimodal age of onset: either before the age of 20 years or after the age of 30 years [
         <a href="#rid33">
          33
         </a>
         ]. SPG31 is caused by mutation in receptor expression-enhancing protein 1 gene (REEP1), a mitochondrial transmembrane protein of unknown function [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18459499">
         <span class="h2">
          Autosomal recessive HSP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autosomal recessive HSP  (
         <a class="graphic graphic_table graphicRef95449" href="/z/d/graphic/95449.html" rel="external">
          table 1
         </a>
         ) is rare in the outbred White population. Unlike autosomal dominant types of HSP, autosomal recessive HSPs are usually associated with a complicated phenotype, with the exceptions of SPG5, 24, 28, and 30 [
         <a href="#rid3">
          3
         </a>
         ]. In addition, the phenotypes of the more common autosomal recessive subtypes, SPG11 and SPG15, are broadly overlapping, with both subtypes typically presenting with early cognitive impairment in childhood followed by gait impairment and spasticity in the second and third decades of life [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG5
         </strong>
         is a predominantly pure form that accounts for approximately 10 percent of autosomal recessive HSP, making it the second most frequent of the autosomal recessive forms [
         <a href="#rid3">
          3
         </a>
         ]. Occasional cases are complicated by axonal neuropathy, distal or generalized muscle atrophy, and white matter lesions detected by brain MRI [
         <a href="#rid2">
          2,36-38
         </a>
         ]. It is caused by mutations in the CYP7B1 gene, which encodes a hydrolase involved in cholesterol metabolism and modification of neurosteroids in the brain [
         <a href="#rid39">
          39
         </a>
         ]. Thus, this disease links cholesterol metabolism to neurodegeneration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG7
         </strong>
         is characterized by either a pure or a complicated phenotype [
         <a href="#rid2">
          2
         </a>
         ]. Onset is mostly in adulthood, although symptoms may start as early as age 11 years [
         <a href="#rid3">
          3
         </a>
         ]. Complicated forms are variably associated with dysarthria, dysphagia, optic disc pallor, axonal neuropathy, and MRI brain abnormalities including vascular-type lesions, cerebellar ataxia, cerebellar atrophy, or cerebral atrophy [
         <a href="#rid2">
          2,40-42
         </a>
         ]. SPG7 is caused by mutation in the paraplegin (SPG7) gene and accounts for 1 to 4 percent of autosomal recessive HSPs [
         <a href="#rid3">
          3,43
         </a>
         ]. There are also reports of SPG7 occurring as an autosomal dominant disorder with heterozygous SPG7 mutations [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG11
         </strong>
         is the most frequent form of autosomal recessive HSP, accounting for 20 to 50 percent of cases [
         <a href="#rid2">
          2,3
         </a>
         ]. SPG11 is caused by mutations in the SPG11 gene that encodes spatacsin, a potential transmembrane protein [
         <a href="#rid45">
          45,46
         </a>
         ]. Onset is typically early and ranges from age 1 to 27 years. Many SPG11 cases are complicated, involving spastic paraparesis variably associated with cognitive impairment, thin corpus callosum or white matter abnormalities on MRI, dysarthria, nystagmus, or arm weakness [
         <a href="#rid2">
          2,45,47,48
         </a>
         ]. SPG11, along with SPG15 discussed below, are two known genetic causes of the Kjellin syndrome, characterized by childhood-onset, progressive spastic paraplegia variably associated with pigmentary retinopathy, intellectual disability, dysarthria, dementia, and distal muscle atrophy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common form of autosomal recessive familial amyotrophic lateral sclerosis, ALS5, has been linked to mutations of the SPG11 gene. The onset is in the second decade. The clinical features of patients with ALS5 differ from those associated with HSP/SPG11 due to the presence of bulbar symptoms, upper motor neuron involvement, and pathologic manifestations of ALS. In addition, the patients with familial ALS5 have not developed the corpus callosum thinning, ocular abnormalities, cognitive deficits, or psychiatric problems that are observed in SPG11-related HSP. (See
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis", section on 'ALS5 (SPG11 gene)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG15
         </strong>
         accounts for 2 to 4 percent of autosomal recessive HSP [
         <a href="#rid2">
          2,3
         </a>
         ]. The complicated phenotype has been associated with the Kjellin syndrome, characterized by early-onset spastic paraplegia variably associated with intellectual disability and/or dementia, dysarthria, distal muscle atrophy, and retinal degeneration. A thin corpus callosum and white matter hyperintensities are usually found on brain MRI [
         <a href="#rid49">
          49
         </a>
         ]. SPG15 is caused by mutation in ZFYVE26 gene [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG20
         </strong>
         , also known as Troyer syndrome, was initially described in Amish kindred from Ohio [
         <a href="#rid51">
          51,52
         </a>
         ]. The syndrome is characterized by onset in early childhood of spastic paraplegia with distal muscle wasting, dysarthria, and difficulty in learning to walk. It is caused by a mutation in spartin (SPG20) gene [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG21
         </strong>
         , or Mast syndrome, is a complicated form of HSP with dementia, cerebellar and extrapyramidal signs that is present at a relatively high frequency among the Old Order Amish [
         <a href="#rid54">
          54
         </a>
         ]. The age of onset ranges from 20 to 40 years [
         <a href="#rid3">
          3
         </a>
         ]. Thin corpus callosum and white matter abnormalities can be seen on MRI. It is caused by a mutation in ACP33 encoding the protein maspardin [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG44
         </strong>
         has been described in three patients from one large Italian family with a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus [
         <a href="#rid56">
          56
         </a>
         ]. MRI and MR spectroscopy imaging were consistent with a hypomyelinating leukoencephalopathy. These three patients had mutation in the GJA12/GJC2, the gene that encodes the gap junction protein connexin 47 (Cx47). Mutations in this gene are also known to cause one form of Pelizaeus-Merzbacher-like disease, a genetically heterogeneous, early-onset dysmyelinating disorder of the central nervous system, characterized by nystagmus, psychomotor delay, progressive spasticity, and cerebellar signs. (See
         <a class="medical medical_review" href="/z/d/html/1693.html" rel="external">
          "Pelizaeus-Merzbacher disease", section on 'Pelizaeus-Merzbacher-like disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18459505">
         <span class="h2">
          X-linked HSP
         </span>
         <span class="headingEndMark">
          —
         </span>
         X-linked HSP  (
         <a class="graphic graphic_table graphicRef95449" href="/z/d/graphic/95449.html" rel="external">
          table 1
         </a>
         ) is associated with four genes (SPG1, 2, 16, and 32). All of these typically cause complicated forms of HSP.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG1
         </strong>
         , the most common X-linked HSP, is characterized by onset in infancy of spastic paraparesis complicated by intellectual disability and variable presence of aphasia, hydrocephalus, and adducted thumbs [
         <a href="#rid2">
          2,3,57
         </a>
         ]. This constellation is also known as the MASA syndrome (for Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs). SPG1 is caused by mutations in the L1 cell adhesion molecule (L1CAM) gene [
         <a href="#rid58">
          58
         </a>
         ]. X-linked hydrocephalus is an allelic syndrome. (See
         <a class="medical medical_review" href="/z/d/html/6174.html" rel="external">
          "Hydrocephalus in children: Physiology, pathogenesis, and etiology", section on 'X-linked hydrocephalus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPG2
         </strong>
         is caused by a mutation in the PLP1 gene. This gene encodes the proteolipid protein (lipophilin), the primary constituent of myelin in the central nervous system [
         <a href="#rid59">
          59
         </a>
         ]. The phenotype is that of spastic paraparesis complicated by variable presence of peripheral neuropathy and white matter lesions on MRI [
         <a href="#rid2">
          2
         </a>
         ]. The age of onset ranges from infancy to the early teenage years. In most cases, there is normal motor development in the first year of life, followed by progressive weakness and spasticity of the legs [
         <a href="#rid60">
          60
         </a>
         ]. Some patients later develop nystagmus, dysarthria, sensory disturbance, optic atrophy, or intellectual disability. SPG2 is allelic to Pelizaeus-Merzbacher disease. (See
         <a class="medical medical_review" href="/z/d/html/1693.html" rel="external">
          "Pelizaeus-Merzbacher disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12449564">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of HSP is based upon the presence of characteristic clinical manifestations (gait impairment with leg spasticity and weakness, often associated with urinary urgency), a family history of a similar disorder (though not universally present), and the exclusion of acquired cause of progressive spastic paraparesis [
         <a href="#rid8">
          8
         </a>
         ]. Identification of a pathogenic variant in an SPG gene by molecular genetic testing confirms the diagnosis [
         <a href="#rid8">
          8
         </a>
         ]. The diagnosis is most easily made when there is a family history of spastic paraplegia and the classic symptoms and signs of pyramidal dysfunction with a chronic course.
        </p>
        <p class="headingAnchor" id="H160850">
         <span class="h2">
          Diagnostic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of a patient with suspected HSP should include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic examination, which typically demonstrates bilateral leg weakness and spasticity (one or the other may predominate, or both may be approximately equal in severity), hyperreflexia, extensor plantar (Babinski) responses, and variably impaired vibration sensation in the distal legs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A three-generation family history to screen for relatives with possible HSP and determine mode of inheritance (eg, autosomal dominant, autosomal recessive, or X-linked)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusion of other disorders (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below) with investigations that include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MRI of the brain and spine with and without contrast to identify structural, demyelinating, and degenerative central nervous system lesions, including cerebellar degeneration in spinocerebellar ataxias that have significant spasticity. In HSP, there may be reduced cross-sectional area of the spinal cord, particularly in the cervical and thoracic regions. In addition, some complicated HSPs can have associated brain abnormalities such as a thin corpus callosum (particularly SPG11, SPG15, SPG32, and SPG21) or hydrocephalus (SPG1).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MR angiography of the spinal cord to look for spinal dural arteriovenous fistula.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebrospinal fluid studies to rule out chronic infections (such as neurosyphilis and neuroborreliosis) and demyelinating conditions (eg, primary progressive multiple sclerosis or an atypical presentation of neuromyelitis optica).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electrodiagnostic testing with nerve conduction studies and electromyography are useful to exclude motor neuron disease and can be abnormal in complicated HSP with anterior horn cell involvement or peripheral neuropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anti-aquaporin-4 antibodies to exclude atypical presentations of neuromyelitis optica.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         C22-26 long chain fatty acid levels to exclude adrenoleukodystrophy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibodies to human T-lymphotropic virus 1 (HTLV-1).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HIV testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum B12 and copper levels (to exclude B12 or copper deficiency).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ophthalmologic studies to look for pigmentary retinopathy in select patients with complicated HSP.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3347502164">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Molecular genetic testing is available for many of the HSPs, and therefore may be useful to confirm the diagnosis or identify potential mimics including spinocerebellar ataxia or Friedreich ataxia. Testing with a multigene panel targeting known HSP-related genes is often used as the first approach to determine a genetic diagnosis; whole-exome sequencing or whole-genome sequencing may identify the causative gene variant when the multigene panel is nondiagnostic [
         <a href="#rid61">
          61-63
         </a>
         ].
        </p>
        <p>
         Genetic testing can be informative even in the absence of family history. As an example, in a study that screened for SPG4 mutations among 146 patients with progressive spastic paraplegia and no known family history after exclusion of neurologic causes, the overall rate of SPG4 mutations was 12 percent [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Of note, the absence of a mutation in a causative gene for HSP does not exclude the diagnosis, since genetic testing does not include all genes that cause HSP.
        </p>
        <p class="headingAnchor" id="H2277011">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of HSP is broad and includes the following disease categories [
         <a href="#rid8">
          8,65
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Motor neuron disease, particularly slowly progressive amyotrophic lateral sclerosis or primary lateral sclerosis. Amyotrophic lateral sclerosis can mimic HSP when it affects the legs without significant amyotrophy or fasciculations. However, progression in amyotrophic lateral sclerosis is usually more rapid than HSP. Because of a lack of lower motor neuron findings, primary lateral sclerosis is more likely to mimic HSP than amyotrophic lateral sclerosis. Unlike HSP, however, primary lateral sclerosis typically affects the bulbar muscles and arms as well. Moreover, vibration sense is spared in both amyotrophic lateral sclerosis and primary lateral sclerosis, while it is often affected in HSP. (See
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Structural compromise of the spinal cord, such as tethered spinal cord syndrome and spinal cord compression. (See
         <a class="medical medical_review" href="/z/d/html/93935.html" rel="external">
          "Closed spinal dysraphism: Clinical manifestations, diagnosis, and management", section on 'Tethered cord syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leukodystrophies and demyelinating disorders, such as:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Progressive multiple sclerosis (see
         <a class="medical medical_review" href="/z/d/html/6229.html" rel="external">
          "Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis", section on 'Course'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">
          "Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Disease onset and pattern'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neuromyelitis optica (see
         <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">
          "Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adrenomyeloneuropathy (see
         <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">
          "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Myeloneuropathy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Krabbe disease [
         <a href="#rid66">
          66
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6188.html" rel="external">
          "Krabbe disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pelizaeus-Merzbacher disease (see
         <a class="medical medical_review" href="/z/d/html/1693.html" rel="external">
          "Pelizaeus-Merzbacher disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Metachromatic leukodystrophy (see
         <a class="medical medical_review" href="/z/d/html/6195.html" rel="external">
          "Metachromatic leukodystrophy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic impairments due to vitamin B12 deficiency (see
         <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">
          "Clinical manifestations and diagnosis of vitamin B12 and folate deficiency", section on 'Neuropsychiatric changes'
         </a>
         ) and copper deficiency (see
         <a class="medical medical_review" href="/z/d/html/16517.html" rel="external">
          "Copper deficiency myeloneuropathy"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vascular malformations, most notably spinal dural arteriovenous fistulas, which typically present after the fifth decade of life with progressive or, less often, fluctuating symptoms including weakness, sensory disturbances, gait abnormalities, sphincter dysfunction, and pain, sometimes exacerbated by exercise. (See
         <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">
          "Disorders affecting the spinal cord", section on 'Vascular malformations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dopa-responsive dystonia, which typically begins in early childhood and is treatable with levodopa in relatively low doses. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Dopa-responsive dystonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metabolic disorders, such as:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Methylene tetrahydrofolate reductase deficiency and cobalamin C deficiency (see
         <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">
          "Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Arginase deficiency and urea cycle defects (see
         <a class="medical medical_review" href="/z/d/html/2929.html" rel="external">
          "Urea cycle disorders: Clinical features and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Biotinidase deficiency
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Phenylketonuria (see
         <a class="medical medical_review" href="/z/d/html/2919.html" rel="external">
          "Overview of phenylketonuria"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Glycine encephalopathy (nonketotic hyperglycinemia)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebral folate deficiency
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebrotendinous xanthomatosis (see
         <a class="medical medical_review" href="/z/d/html/1692.html" rel="external">
          "Cerebrotendinous xanthomatosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sjögren-Larsson syndrome (see
         <a class="medical medical_review" href="/z/d/html/1699.html" rel="external">
          "Sjögren-Larsson syndrome"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adult polyglucosan body disease (see
         <a class="medical medical_review" href="/z/d/html/2937.html" rel="external">
          "Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)", section on 'Clinical features'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nucleoside phosphorylase deficiency (see
         <a class="medical medical_review" href="/z/d/html/3943.html" rel="external">
          "Purine nucleoside phosphorylase deficiency"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency (see
         <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">
          "Hyperkinetic movement disorders in children", section on 'Lesch-Nyhan syndrome'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infectious diseases, particularly:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tropical spastic paraparesis caused by human T-lymphotropic virus 1 (see
         <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">
          "Disorders affecting the spinal cord", section on 'HTLV-I myelopathy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Human immunodeficiency virus (see
         <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">
          "Disorders affecting the spinal cord", section on 'AIDS myelopathy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurosyphilis (see
         <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">
          "Neurosyphilis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neuroborreliosis (see
         <a class="medical medical_review" href="/z/d/html/15247.html" rel="external">
          "Nervous system Lyme disease", section on 'Lyme encephalomyelitis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary ataxias with significant spasticity [
         <a href="#rid67">
          67
         </a>
         ]; these can present with an HSP-like onset if the ataxia is confined to the spastic lower extremities. Examples include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Certain spinocerebellar ataxias (see
         <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">
          "Autosomal dominant spinocerebellar ataxias"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Friedreich ataxia (see
         <a class="medical medical_review" href="/z/d/html/6224.html" rel="external">
          "Friedreich ataxia"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autosomal recessive spastic ataxia of Charlevoix-Saguenay (see
         <a class="medical medical_review" href="/z/d/html/14134.html" rel="external">
          "Overview of cerebellar ataxia in adults", section on 'Autosomal recessive ataxias'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early-onset dementias, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Amyotrophic lateral sclerosis with frontotemporal dementia (see
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Cognitive symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis", section on 'C9ORF72 gene'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Familial Alzheimer disease (see
         <a class="medical medical_review" href="/z/d/html/16195.html" rel="external">
          "Genetics of Alzheimer disease", section on 'Early-onset Alzheimer disease'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The diagnostic work-up should address this broad differential diagnosis. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12449572">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Like most neurodegenerative diseases, there is no disease-modifying treatment for HSP. However, much can be done to help the symptoms. The goal of symptomatic treatment is to improve mobility, increase range of motion, and relieve the discomfort associated with spasticity. Supportive treatment can be subdivided into pharmacologic treatment of spasticity and physical therapy and rehabilitation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacologic therapy of spasticity
         </strong>
         – There are several pharmacological approaches to improve spasticity. These include oral
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         , oral
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         (starting at the lowest dose and titrating slowly as tolerated), and botulinum toxin injections into spastic muscles. Benzodiazepines also help in reducing spasticity but their use is now limited because of side effects. To improve their tolerance, antispasticity drugs are started at a low dose and titrated up slowly. The most common side effect of these agents is sedation. Intrathecal baclofen can be used in the more severe cases. Spastic bladder and its associated urge symptoms can be treated with anticholinergic agents such as
         <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">
          oxybutynin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical medicine and rehabilitation
         </strong>
         – Under the guidance of physical and occupational therapists and rehabilitation physicians, patients with HSP should be encouraged to exercise and engage in therapy that focuses on stretching, reducing spasticity, and improving balance and strength. Some patients can benefit from assistive devices such as ankle-foot orthoses, walkers, or wheelchairs.
        </p>
        <p>
        </p>
        <p>
         As with any genetic disease, genetic counseling can help patients learn about the disease transmission and the risk of passing on genetic mutations to their children, particularly for those planning on starting families (see
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing"
         </a>
         ). However, genetic counseling can be difficult when the mode of transmission is not evident or when there is variable penetrance. In particular, the frequency of de novo mutations causing autosomal dominant HSP is uncertain, and the full phenotypic spectrum and genetic penetrance of many types of HSP are unknown [
         <a href="#rid2">
          2
         </a>
         ]. Counseling with respect to SPG7 should account for the observation that SPG7 is associated with both autosomal dominant and autosomal recessive inheritance patterns (see
         <a class="local">
          'Autosomal recessive HSP'
         </a>
         above). Prenatal genetic testing is possible for certain forms of HSP if the disease-causing mutation has been identified in an affected family member [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2276865">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pure HSPs do not typically affect lifespan, although they can have a significant deleterious impact on the quality of life.
        </p>
        <p>
         The rate of progression and severity of different types of HSP is highly variable among and even within specific genetic types. Several patterns of progression have been described:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A relatively nonprogressive course
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progressive worsening that stabilizes over time
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inexorable decline
        </p>
        <p>
        </p>
        <p>
         With early childhood onset, the symptoms of HSP tend to be relatively non-progressive over many years and can mimic the spastic diplegia form of cerebral palsy [
         <a href="#rid2">
          2
         </a>
         ]. A subset of children experience a decline in gait for 5 to 10 years, followed by a "functional plateau" with relatively little or no further decline. With onset later in childhood or adulthood, the most typical pattern is slow but relentless progression over many years, though some individuals experience variable phases of faster or slower progression.
        </p>
        <p>
         In a cohort of 608 cases of HSP, progression to loss of independent ambulation occurred at a median disease duration of 22 years, and wheelchair dependency at a median disease duration of 37 years [
         <a href="#rid68">
          68
         </a>
         ]. Factors associated with more severe disease included longer disease duration, later age of onset, and the SPG11 genotype.
        </p>
        <p class="headingAnchor" id="H2276872">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary spastic paraplegia (HSP) refers to a group of familial diseases that are characterized primarily by progressive degeneration of the corticospinal tracts. Clinically, they present with lower limb spasticity and weakness. HSPs are clinically differentiated into "pure" forms if spastic paraplegia with bladder involvement is the only clinical finding, and "complicated" (or complex) forms if there are additional neurologic or systemic abnormalities. The genetic classification of HSP is based upon mode of inheritance, chromosomal locus, and causative mutation. The genetic loci are designated as SPG and are numbered sequentially as SPG1, SPG2, SPG3, and so on  (
         <a class="graphic graphic_table graphicRef95449" href="/z/d/graphic/95449.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While the HSPs are genetically diverse, a shared pathway for these disorders is length-dependent degeneration of the corticospinal tract axons. Laboratory and genetic studies suggest a variety of molecular causes for HSP. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In most cases, HSP presents with gait impairment caused by leg weakness and spasticity. Bladder dysfunction is relatively common. With the pure types of HSP, the symptoms are restricted to involvement of the longest tracts of the spinal cord. Speech is not affected, nor is there weakness in the bulbar muscles or arms. With the complicated types of HSP, paraplegia coexists with additional neurologic or systemic derangements, such as peripheral neuropathy, MRI brain abnormalities, cognitive impairment, ataxia, distal muscle atrophy, visual loss, or epilepsy. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autosomal dominant HSPs usually cause a pure HSP phenotype. SPG4 and SPG3A are the most common autosomal dominant HSPs. By contrast, autosomal recessive HSPs are usually associated with a complicated phenotype. SPG5 and SPG11 are the most common autosomal recessive types. X-linked HSPs typically cause complicated forms of HSP. (See
         <a class="local">
          'Autosomal dominant HSP'
         </a>
         above and
         <a class="local">
          'Autosomal recessive HSP'
         </a>
         above and
         <a class="local">
          'X-linked HSP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of HSP is based upon the presence of characteristic clinical manifestations (gait impairment with leg spasticity and weakness, often associated with urinary urgency), a family history of a similar disorder (though not universally present), the exclusion of other disorders, and, increasingly, on molecular genetic testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The differential diagnosis of HSP is broad and includes the following disease categories (see
         <a class="local">
          'Differential diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Motor neuron disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Structural compromise of the spinal cord, such as tethered cord syndrome
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vascular malformations of the spinal cord, particularly spinal dural arteriovenous fistula
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leukodystrophies such as adult-onset adrenoleukodystrophy and adult-onset metachromatic leukodystrophy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Demyelinating disorders, including progressive multiple sclerosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dopa-responsive dystonia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Metabolic disorders, such as methylene tetrahydrofolate reductase deficiency and cobalamin C deficiency
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infectious diseases, particularly tropical spastic paraparesis and human immunodeficiency virus
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hereditary ataxias associated with significant spasticity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no disease-modifying treatment for HSP. The goal of symptomatic treatment is to improve mobility, increase range of motion, and relieve the discomfort associated with spasticity. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of progression and severity of different types of HSP is highly variable. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet 1983; 1:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol 2013; 126:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denora PS, Santorelli FM, Bertini E. Hereditary spastic paraplegias: one disease for many genes, and still counting. Handb Clin Neurol 2013; 113:1899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novarino G, Fenstermaker AG, Zaki MS, et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 2014; 343:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chase A. Genetics: Exome sequencing sheds light on hereditary spastic paraplegia. Nat Rev Neurol 2014; 10:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coutinho P, Ruano L, Loureiro JL, et al. Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study. JAMA Neurol 2013; 70:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Depienne C, Stevanin G, Brice A, Durr A. Hereditary spastic paraplegias: an update. Curr Opin Neurol 2007; 20:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shribman S, Reid E, Crosby AH, et al. Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Lancet Neurol 2019; 18:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loureiro JL, Brandão E, Ruano L, et al. Autosomal dominant spastic paraplegias: a review of 89 families resulting from a portuguese survey. JAMA Neurol 2013; 70:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott CJ, Burness CE, Kirby J, et al. Clinical features of hereditary spastic paraplegia due to spastin mutation. Neurology 2006; 67:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Züchner S. The genetics of hereditary spastic paraplegia and implications for drug therapy. Expert Opin Pharmacother 2007; 8:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haberlová J, Claeys KG, Zámecník J, et al. Extending the clinical spectrum of SPG3A mutations to a very severe and very early complicated phenotype. J Neurol 2008; 255:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ivanova N, Claeys KG, Deconinck T, et al. Hereditary spastic paraplegia 3A associated with axonal neuropathy. Arch Neurol 2007; 64:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusco C, Frattini D, Farnetti E, et al. Very early onset and severe complicated phenotype caused by a new spastic paraplegia 3A gene mutation. J Child Neurol 2012; 27:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Maawali A, Rolfs A, Klingenhaeger M, Yoon G. Hereditary spastic paraplegia associated with axonal neuropathy: a novel mutation of SPG3A in a large family. J Clin Neuromuscul Dis 2011; 12:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao X, Alvarado D, Rainier S, et al. Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia. Nat Genet 2001; 29:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webb S, Coleman D, Byrne P, et al. Autosomal dominant hereditary spastic paraparesis with cognitive loss linked to chromosome 2p. Brain 1998; 121 ( Pt 4):601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen JE, Johnsen B, Koefoed P, et al. Hereditary spastic paraplegia with cerebellar ataxia: a complex phenotype associated with a new SPG4 gene mutation. Eur J Neurol 2004; 11:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer T, Schwan A, Dullinger JS, et al. Early-onset ALS with long-term survival associated with spastin gene mutation. Neurology 2005; 65:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orlacchio A, Kawarai T, Totaro A, et al. Hereditary spastic paraplegia: clinical genetic study of 15 families. Arch Neurol 2004; 61:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chelban V, Tucci A, Lynch DS, et al. Truncating mutations in SPAST patients are associated with a high rate of psychiatric comorbidities in hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry 2017; 88:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillespie MK, Humphreys P, McMillan HJ, Boycott KM. Association of Early-Onset Spasticity and Risk for Cognitive Impairment With Mutations at Amino Acid 499 in SPAST. J Child Neurol 2018; 33:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svenson IK, Kloos MT, Gaskell PC, et al. Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations. Neurogenetics 2004; 5:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazan J, Fonknechten N, Mavel D, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet 1999; 23:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solowska JM, Baas PW. Hereditary spastic paraplegia SPG4: what is known and not known about the disease. Brain 2015; 138:2471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rainier S, Chai JH, Tokarz D, et al. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am J Hum Genet 2003; 73:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du J, Hu YC, Tang BS, et al. Expansion of the phenotypic spectrum of SPG6 caused by mutation in NIPA1. Clin Neurol Neurosurg 2011; 113:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svenstrup K, Møller RS, Christensen J, et al. NIPA1 mutation in complex hereditary spastic paraplegia with epilepsy. Eur J Neurol 2011; 18:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valdmanis PN, Meijer IA, Reynolds A, et al. Mutations in the KIAA0196 gene at the SPG8 locus cause hereditary spastic paraplegia. Am J Hum Genet 2007; 80:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blair MA, Ma S, Hedera P. Mutation in KIF5A can also cause adult-onset hereditary spastic paraplegia. Neurogenetics 2006; 7:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito D, Suzuki N. Seipinopathy: a novel endoplasmic reticulum stress-associated disease. Brain 2009; 132:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Windpassinger C, Auer-Grumbach M, Irobi J, et al. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 2004; 36:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beetz C, Schüle R, Deconinck T, et al. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain 2008; 131:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Züchner S, Wang G, Tran-Viet KN, et al. Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. Am J Hum Genet 2006; 79:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pensato V, Castellotti B, Gellera C, et al. Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. Brain 2014; 137:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biancheri R, Ciccolella M, Rossi A, et al. White matter lesions in spastic paraplegia with mutations in SPG5/CYP7B1. Neuromuscul Disord 2009; 19:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkinson PA, Crosby AH, Turner C, et al. A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia. Neurology 2003; 61:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criscuolo C, Filla A, Coppola G, et al. Two novel CYP7B1 mutations in Italian families with SPG5: a clinical and genetic study. J Neurol 2009; 256:1252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsaousidou MK, Ouahchi K, Warner TT, et al. Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am J Hum Genet 2008; 82:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warnecke T, Duning T, Schirmacher A, et al. A novel splice site mutation in the SPG7 gene causing widespread fiber damage in homozygous and heterozygous subjects. Mov Disord 2010; 25:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klebe S, Depienne C, Gerber S, et al. Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. Brain 2012; 135:2980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Gassen KL, van der Heijden CD, de Bot ST, et al. Genotype-phenotype correlations in spastic paraplegia type 7: a study in a large Dutch cohort. Brain 2012; 135:2994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Michele G, De Fusco M, Cavalcanti F, et al. A new locus for autosomal recessive hereditary spastic paraplegia maps to chromosome 16q24.3. Am J Hum Genet 1998; 63:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Ferrero E, Coto E, Beetz C, et al. SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. Clin Genet 2013; 83:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevanin G, Santorelli FM, Azzedine H, et al. Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet 2007; 39:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozner T, Regensburger M, Engelhorn T, et al. Janus-faced spatacsin (SPG11): involvement in neurodevelopment and multisystem neurodegeneration. Brain 2020; 143:2369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winner B, Uyanik G, Gross C, et al. Clinical progression and genetic analysis in hereditary spastic paraplegia with thin corpus callosum in spastic gait gene 11 (SPG11). Arch Neurol 2004; 61:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           França MC Jr, Yasuda CL, Pereira FR, et al. White and grey matter abnormalities in patients with SPG11 mutations. J Neurol Neurosurg Psychiatry 2012; 83:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goizet C, Boukhris A, Maltete D, et al. SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum. Neurology 2009; 73:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanein S, Martin E, Boukhris A, et al. Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am J Hum Genet 2008; 82:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proukakis C, Cross H, Patel H, et al. Troyer syndrome revisited. A clinical and radiological study of a complicated hereditary spastic paraplegia. J Neurol 2004; 251:1105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross HE, McKusick VA. The Troyer syndrome. A recessive form of spastic paraplegia with distal muscle wasting. Arch Neurol 1967; 16:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel H, Cross H, Proukakis C, et al. SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat Genet 2002; 31:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross HE, McKusick VA. The mast syndrome. A recessively inherited form of presenile dementia with motor disturbances. Arch Neurol 1967; 16:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson MA, Cross H, Proukakis C, et al. Maspardin is mutated in mast syndrome, a complicated form of hereditary spastic paraplegia associated with dementia. Am J Hum Genet 2003; 73:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orthmann-Murphy JL, Salsano E, Abrams CK, et al. Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain 2009; 132:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jouet M, Rosenthal A, Armstrong G, et al. X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. Nat Genet 1994; 7:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenwrick S, Watkins A, De Angelis E. Neural cell recognition molecule L1: relating biological complexity to human disease mutations. Hum Mol Genet 2000; 9:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diehl HJ, Schaich M, Budzinski RM, Stoffel W. Individual exons encode the integral membrane domains of human myelin proteolipid protein. Proc Natl Acad Sci U S A 1986; 83:9807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue K. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics 2005; 6:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Méreaux JL, Banneau G, Papin M, et al. Clinical and genetic spectra of 1550 index patients with hereditary spastic paraplegia. Brain 2022; 145:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panwala TF, Garcia-Santibanez R, Vizcarra JA, et al. Childhood-Onset Hereditary Spastic Paraplegia (HSP): A Case Series and Review of Literature. Pediatr Neurol 2022; 130:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saputra L, Kumar KR. Challenges and Controversies in the Genetic Diagnosis of Hereditary Spastic Paraplegia. Curr Neurol Neurosci Rep 2021; 21:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Depienne C, Tallaksen C, Lephay JY, et al. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases. J Med Genet 2006; 43:259.
          </a>
         </li>
         <li class="breakAll">
          Hedera P. Hereditary spastic paraplegia overview. In: GeneReviews [Internet], Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1509/ (Accessed on January 25, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajaj NP, Waldman A, Orrell R, et al. Familial adult onset of Krabbe's disease resembling hereditary spastic paraplegia with normal neuroimaging. J Neurol Neurosurg Psychiatry 2002; 72:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Bot ST, Willemsen MA, Vermeer S, et al. Reviewing the genetic causes of spastic-ataxias. Neurology 2012; 79:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schüle R, Wiethoff S, Martus P, et al. Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. Ann Neurol 2016; 79:646.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14152 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6133167" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Classification of the hereditary ataxias and paraplegias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23897027" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23622413" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hereditary spastic paraplegias: one disease for many genes, and still counting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24482476" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24566998" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genetics: Exome sequencing sheds light on hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23609960" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17992088" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hereditary spastic paraplegias: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31377012" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23400676" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Autosomal dominant spastic paraplegias: a review of 89 families resulting from a portuguese survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16832076" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical features of hereditary spastic paraplegia due to spastin mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17661726" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The genetics of hereditary spastic paraplegia and implications for drug therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18446315" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Extending the clinical spectrum of SPG3A mutations to a very severe and very early complicated phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17502470" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hereditary spastic paraplegia 3A associated with axonal neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22378671" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Very early onset and severe complicated phenotype caused by a new spastic paraplegia 3A gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21321493" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hereditary spastic paraplegia associated with axonal neuropathy: a novel mutation of SPG3A in a large family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11685207" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9577388" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Autosomal dominant hereditary spastic paraparesis with cognitive loss linked to chromosome 2p.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15667412" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hereditary spastic paraplegia with cerebellar ataxia: a complex phenotype associated with a new SPG4 gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16009903" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Early-onset ALS with long-term survival associated with spastin gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15210521" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hereditary spastic paraplegia: clinical genetic study of 15 families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28572275" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Truncating mutations in SPAST patients are associated with a high rate of psychiatric comorbidities in hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29421991" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Association of Early-Onset Spasticity and Risk for Cognitive Impairment With Mutations at Amino Acid 499 in SPAST.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15248095" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10610178" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26094131" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hereditary spastic paraplegia SPG4: what is known and not known about the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14508710" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21419568" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Expansion of the phenotypic spectrum of SPG6 caused by mutation in NIPA1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21599812" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : NIPA1 mutation in complex hereditary spastic paraplegia with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17160902" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mutations in the KIAA0196 gene at the SPG8 locus cause hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16489470" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mutation in KIF5A can also cause adult-onset hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18790819" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Seipinopathy: a novel endoplasmic reticulum stress-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14981520" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18321925" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16826527" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24833714" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19187859" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : White matter lesions in spastic paraplegia with mutations in SPG5/CYP7B1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12874406" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19363635" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Two novel CYP7B1 mutations in Italian families with SPG5: a clinical and genetic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18252231" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20108356" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A novel splice site mutation in the SPG7 gene causing widespread fiber damage in homozygous and heterozygous subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23065789" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22964162" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Genotype-phenotype correlations in spastic paraplegia type 7: a study in a large Dutch cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9634528" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A new locus for autosomal recessive hereditary spastic paraplegia maps to chromosome 16q24.3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22571692" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17322883" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32355960" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Janus-faced spatacsin (SPG11): involvement in neurodevelopment and multisystem neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14732628" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical progression and genetic analysis in hereditary spastic paraplegia with thin corpus callosum in spastic gait gene 11 (SPG11).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22696581" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : White and grey matter abnormalities in patients with SPG11 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19805727" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18394578" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15372254" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Troyer syndrome revisited. A clinical and radiological study of a complicated hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6022528" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The Troyer syndrome. A recessive form of spastic paraplegia with distal muscle wasting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12134148" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6024251" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The mast syndrome. A recessively inherited form of presenile dementia with motor disturbances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14564668" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Maspardin is mutated in mast syndrome, a complicated form of hereditary spastic paraplegia associated with dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19056803" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7920659" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10767310" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Neural cell recognition molecule L1: relating biological complexity to human disease mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3467339" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Individual exons encode the integral membrane domains of human myelin proteolipid protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15627202" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34983064" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Clinical and genetic spectra of 1550 index patients with hereditary spastic paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35303589" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Childhood-Onset Hereditary Spastic Paraplegia (HSP): A Case Series and Review of Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33646413" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Challenges and Controversies in the Genetic Diagnosis of Hereditary Spastic Paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16055926" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16055926" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11971051" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Familial adult onset of Krabbe's disease resembling hereditary spastic paraplegia with normal neuroimaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23033504" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Reviewing the genetic causes of spastic-ataxias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26856398" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
